Compass Pathways Stock Surges 40% Following White House Executive Order on Psychedelic Therapies
Compass Pathways (NASDAQ: CMPS) stock surged over 40% following a White House Executive Order aimed at accelerating psychedelic drug research and approvals. The order supports Compass's synthetic psilocybin therapy, COMP360, which has shown positive results in phase 3 trials and is under FDA review.
Topics: biotechnology government policy mental health treatment psychedelic drugs stock price movement